Passage Bio-Aktie erreicht 52-Wochen-Tief at 0.54 US-Dollar Von Investing.com

In a herausfordernden Marktumfeld, the Action of Passage Bio Inc (PASG) bought a 52-Wochen-Tief and traded for 0.54 US-Dollar. If biotechnology research is concerned, when it comes to gene therapies for seltene, monogenic effects of the central nerve systems are specialized, which are reflected in the course of time, which reflects all general trends in the biotech sector more broadly. The forecast of the forecast is that there is an active effect of 6.21% in the annual distribution. The level of these years is volatile and the high risks of investing in biotechnology investments, without any certainty, that will take place in the stages of the medical sector. Passage Bio’s Entwicklung offers more brand analysis from industry analysts and investors.

In other cases, Passage Bio, Inc. various clinical data for your gene therapy product PBFT02 performed with the treatment of frontotemporal demenz with GRN mutations. Therapy is potentially developed, progranulin levels are high, and lysosomal histopathology is extensive. Passage Bio has provided a strategic description of the treatment of GM1-Gangliosidosis, Krabbe-Krankheit and metachromatic Leukodystrophy and GEMMA Biotherapeutics, Inc. The deal has secured a quick delivery of 10 million US dollars and could generate even more money, causing a geschaftliche meilenstein to be knüpft.

Analysts from Canaccord Genuity have based their Kaufempfehlung for Passage Bio-researchers on positive Zwischenergebnissen from upliFT-D Phase 1/2-Study. If you are aware of the current options, a note of the Nasdaq listing that is hereditary, a delisting-benachrichtigung-droht.

In one of the directives of the last century, Passage Bio recognized Thomas Kassberg as Class I director and supervisor of the Prüfungsausschussses. Kassberg, one of the state treasures in biotechnology that is being developed, has not chosen any basic option as part of the Vergütungspakets. This is how the US Food and Drug Administration (FDA) has treated a PBFT02 in patients with frontotemporal demenz with C9orf72 gene mutations to evaluate.

InvestingPro Acknowledgment

Während Passage Bio Inc (PASG) with its 52-Wochen-Tief kämpft, liefern InvestingPro-Daten sisterätzlichen Kontext for financial situation of Unternehmens. The market capitalization of the Unternehmens had a modest value of US$34.03 million, reflecting the potential holdings in the market more broadly.

InvestingPro-Tipps have some critical aspects of PASG’s financial outlook. The “expired rapid payment” and “leads to a successful gross profit margin”, was with the additional support, which means that the Biotech-Unternehmen in frühen Stadien gegenübersehen, which strongly invest in Research and Entwicklung. It is possible that the Promotion will “generate greater revenue in the future”, where InvestingPro data shows a return of 53.89% on the 6-month trend.

Positive for the brands is that the PASG “more money as debt in the blessing of Bilanz hält”, a certain financing flexibility in the purchase of a sea fishing development pipeline was possible. Allerdings “erwarten Analysten nicht, dass das Unternehmen in diesem Jahr profitable sein wird”, was the speculative character of Investitionen in Biotech-Unternehmen in Frühstadium unterstreicht.

For investors, who are among the financial institutions of the bio-passage, InvestingPro offers 5 other tips and an ongoing journey from real measurements, an investment separation in this volatile sector in our sector.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.